UroGen Pharma (URGN) reported Q2 EPS of ($1.18), $0.10 better than the analyst estimate of ($1.28). Revenue for the quarter came in at $16.6 million versus the consensus estimate of $17.22 million.
GUIDANCE:
UroGen Pharma sees FY2022 revenue of $70-80 million, versus the consensus of $75.2 million.